Veracyte, Inc. (VCYT): Operating Cash Flow
$136.31M
Year ended 2025-12-31
$178.38M
Trailing 12 months to 2026-06-30
+162.5%
3-year compound annual growth
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $136.31M | +81.5% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $75.10M | +69.8% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $44.22M | +486.9% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $7.54M | n/m | 2025-02-28, From 2022-01-01 |
| 2021-12-31 | -$31.62M | n/m | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | -$9.71M | n/m | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | -$3.23M | n/m | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | -$13.52M | n/m | 2021-02-22, From 2018-01-01 |
| 2017-12-31 | -$23.91M | n/m | 2020-02-25, From 2017-01-01 |
| 2016-12-31 | -$27.98M | n/m | 2019-02-25, From 2016-01-01 |
| 2015-12-31 | -$26.96M | n/m | 2018-02-27, From 2015-01-01 |
| 2014-12-31 | -$27.63M | n/m | 2017-03-01, From 2014-01-01 |
| 2013-12-31 | -$19.16M | n/m | 2016-03-14, From 2013-01-01 |
| 2012-12-31 | -$7.17M | n/m | 2015-03-25, From 2012-01-01 |
| 2011-12-31 | -$13.52M | n/a | 2014-03-20, From 2011-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Veracyte, Inc. (VCYT) | 2025-12-31 | $136.31M | +81.5% |
| CareDx, Inc. (CDNA) | 2025-12-31 | $42.03M | +10.5% |
| Castle Biosciences Inc (CSTL) | 2025-12-31 | $64.35M | -0.8% |
| Caris Life Sciences, Inc. (CAI) | 2025-12-31 | $83.16M | n/m |
| Fulgent Genetics, Inc. (FLGT) | 2025-12-31 | -$101.64M | n/m |
| BillionToOne, Inc. (BLLN) | 2025-12-31 | $24.59M | n/m |
| Guardant Health, Inc. (GH) | 2025-12-31 | -$184.76M | n/m |
| GRAIL, Inc. (GRAL) | 2025-12-31 | -$299.01M | n/m |
| RadNet, Inc. (RDNT) | 2025-12-31 | $298.82M | +28.2% |
Compare VCYT, CDNA, CSTL, CAI side by side · Screen every company in Services-Medical Laboratories ↗